



© Copyright 2012 Oregon State University. All Rights Reserved

Drug Use Research & Management Program  
OHA Division of Medical Assistance Programs  
500 Summer Street NE, E35; Salem, OR 97301-1079  
Phone 503-947-5220 | Fax 503-947-1119



### Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, June 4th, 2026 1:00 - 5:00 PM

Remote Meeting via Zoom Platform

#### MEETING AGENDA

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.**

#### I. CALL TO ORDER

- |         |   |   |
|---------|---|---|
| 1:00 PM | <ul style="list-style-type: none"> <li>A. Roll Call &amp; Introductions</li> <li>B. Conflict of Interest Declaration</li> <li>C. Approval of Agenda and Minutes</li> <li>D. Department Update</li> <li>E. Mental Health Clinical Advisory Group Update</li> </ul> | <ul style="list-style-type: none"> <li>R. Citron (OSU)</li> <li>R. Citron (OSU)</li> <li>R. Citron (OSU)</li> <li>A. Gibler (OHA)</li> <li>A. Gibler (OHA)</li> </ul> |
|---------|---|---|

1:20 PM	II. CONSENT AGENDA TOPICS	S. Ramirez (Chair)
---------	---------------------------	--------------------

- A. Inhalers for Asthma/COPD Literature Scan
- B. Oncology Prior Authorization Updates
- C. Orphan Drug Policy Updates
  - 1. Public Comment

1:25 PM	III. PDL OLD BUSINESS	S. Servid (OSU)
---------	-----------------------	-----------------

- A. Healthier Oregon Policy Update
  - 1. Topical Antifungals
  - 2. Antidiarrheals
  - 3. Antacids, Proton Pump Inhibitors
  - 4. Nasal Allergy Inhalers
  - 5. Ophthalmic Medications for Allergies
  - 6. Laxatives for Chronic Constipation

1:30 PM	IV. DUR ACTIVITIES
---------	--------------------

- |   |   |
|---|---|
| <ul style="list-style-type: none"> <li>A. Quarterly Utilization Report</li> <li>B. P &amp; T Methods</li> <li>C. P &amp; T Procedures</li> <li>D. ProDUR Report</li> <li>E. RetroDUR Report</li> <li>F. Oregon State Drug Review           <ul style="list-style-type: none"> <li>1. Respiratory Syncytial Virus (RSV) Prevention Update</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>R. Citron (OSU)</li> <li>S. Servid (OSU)</li> <li>S. Servid (OSU)</li> <li>L. Starkweather (Gainwell)</li> <li>D. Engen (OSU)</li> <li>K. Sentena (OSU)</li> </ul> |
|---|---|

2. Evaluating the Quality of Evidence from Observational Studies: Lessons from Acetaminophen Use in Pregnancy

#### V. NEW BUSINESS

- |         |   |                   |
|---------|---|-------------------|
| 1:55 PM | A. Topoisomerase II Inhibitors Class Update with New Drug Evaluation <ol style="list-style-type: none"><li>1. Class Update/Prior Authorization Criteria</li><li>2. Nuzolvece (zoliflodacin) New Drug Evaluation</li><li>3. Public Comment</li><li>4. Discussion and Clinical Recommendations to OHA</li></ol> | K. Sentena (OSU)  |
| 2:10 PM | B. Zycubo (Copper Histidinate) Orphan Drug Evaluation <ol style="list-style-type: none"><li>1. Orphan Drug Evaluation</li><li>2. Prior Authorization Criteria</li><li>3. Public Comment</li><li>4. Discussion and Clinical Recommendations to OHA</li></ol>   | S. Fletcher (OSU) |
| 2:20 PM | C. Benzodiazepines Focused Scan for Catatonia <ol style="list-style-type: none"><li>1. Literature Scan</li><li>2. Prior Authorization Update</li><li>3. Public Comment</li><li>4. Discussion and Clinical Recommendations</li></ol>   | D. Engen (OSU)    |
| 2:35 PM | D. Cardamyst™ (etripamil) New Drug Evaluation <ol style="list-style-type: none"><li>1. New Drug Evaluation</li><li>2. Prior Authorization Criteria</li><li>3. Public Comment</li><li>4. Discussion and Clinical Recommendations to OHA</li></ol>  | D. Moretz (OSU)   |
| 2:50 PM | BREAK   |                   |
| 3:05 PM | E. Spinal Muscular Atrophy Class Update <ol style="list-style-type: none"><li>1. Class Update/Prior Authorization Criteria</li><li>2. Itvisma (onasemnogene abeparvec) New Drug Evaluation</li><li>3. Public Comment</li><li>4. Discussion and Clinical Recommendations to OHA</li></ol>                      | D. Moretz (OSU)   |
| 3:25 PM | F. Myasthenia Gravis DERP Report <ol style="list-style-type: none"><li>1. DERP Report/Prior Authorization Criteria</li><li>2. Public Comment</li><li>3. Discussion and Clinical Recommendations to OHA</li></ol>  | S. Fletcher (OSU) |
| 3:40 PM | G. Loargys (pegzilarginase) Orphan Drug Evaluation <ol style="list-style-type: none"><li>1. Orphan Drug Evaluation/Prior Authorization Criteria</li><li>2. Public Comment</li></ol>   | D. Moretz (OSU)   |

3. Discussion and Clinical Recommendations to OHA

3:55 PM VI. EXECUTIVE SESSION

4:50 PM VII. RECONVENE for PUBLIC RECOMMENDATIONS

VIII. ADJOURN